Kyntra Bio, Inc. (NASDAQ:KYNB)
| Market Cap | $6.32M-81.8% |
| Revenue (ttm) | $5.30M+104.5% |
| Net Income | $34.88M-78.7% |
| EPS | $8.62+1557.7% |
| Shares Out | 4.05M |
| PE Ratio | 0.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,379 |
| Open | $1.81 |
| Previous Close | $1.83 |
| Day's Range | $1.54 - $1.81 |
| 52-Week Range | $1.54 - $10.47 |
| Beta | 1.10 |
| Analysts | Hold |
| Price Target | $28.00(+1694.87%) |
| Earnings Date | Mar 15, 2027 |
About KYNB
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating KYNB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 15, 2027Earnings report
$KYNB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in KYNB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KYNB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KYNB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KYNB Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New KYNB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KYNB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KYNB
| VTIVanguard Morningstar Total Stock Market ETF | $411.19K |
| VXFVanguard Extended Market ETF | $193.15K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from KYNB’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple analyst downgrades on price targets coupled with Q3 earnings miss on revenue, though some analysts maintain buy ratings.
